Briefly, we present a case of an NSCLC patient with acquired MET amplification at a low GCN level (GCN = 3) following resistance to EGFR-TKI, achieving a notable response to the combination of savolitinib and osimertinib. Here, MET is linked to non-small cell lung carcinoma.